Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Por Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L., de Pril, V., Humphrey, R., Lebbé, C.
Publicado em 2013

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Por Lebbé, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., O'Day, S. J., Konto, C., Cykowski, L., McHenry, M. B., Wolchok, J. D.
Publicado no Ann Oncol (2014)